Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the manufacturing of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry, and also the development, manufacturing and marketing of biotechnology-based for products for the human pharmaceutical market. The company continues full disclosure of its financial and operational results, which can be accessed by visiting the company website at www.Polydex.com. Product information is available at www.dextran.ca Company website: www.Polydex.com
“We earlier reported our expectations for first quarter sales to be short of the sales goals we would normally hope for, due to the production lag time for our specialized Dextran Sulphate product, and are looking forward to delivering current orders for that product in the second and third quarter of this fiscal year,” said George Usher, President and CEO. “Additionally,” he added, “we have continued to investigate new markets for our powdered products and Native Dextran for industrial uses. We are actively pursuing these new markets and collaborations in an effort to maintain profitability in fiscal 2022.” As countries around the world are able to control COVID and African Swine Fever, we are encouraged that our careful cash management has enabled the company to retain its complete experienced workforce and be well positioned to meet demand for our specialized products.
The Company’s publicly traded shares continue to be quoted on the OTC Pink Sheet platform (www.otcmarkets.com/stock/POLXF/quote). The outbreak of African Swine Fever combined with the strengthening Canadian Dollar resulted in the significant decrease in gross sales and profit.
Source www.globenewswire.com Investor Relations: Linda Hughes, PolydexIR@gmail.com
Contact: Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited, including, without limitation, statements regarding expectations about future revenues or business opportunities or potential research projects. These statements are typically identified by use of words like “may”, “could”, “might”, “expect”, “anticipate”, “believe”, or similar words. Actual events or results may differ materially from the Company’s expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities. Other risk factors discussed in the Company’s financial reports may also affect the actual results achieved by the Company.
The News Highlights
- Polydex Pharmaceuticals Issues First Quarter Financial
- Check the latest News news updates and information about business, finance and more.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week